At the 2025 annual meeting of the Society for Neuroscience in San Diego this week, Catherine Woolley’s plenary lecture was an ...

In a verbal sparring over who can deliver the lowest drug prices in the U.S., several Senate Democrats are urging President ...

Tempest Therapeutics Inc. entered definitive agreements approved by its board to acquire certain dual-targeting CAR T ...

Med-tech M&A activity cooled in October, with the total disclosed deal value reaching $1.68 billion, a step down from ...

Dexcom Inc. received U.S. FDA clearance for its Smart Basal CGM-integrated basal insulin dosing optimizer. Designed for adults with type 2 diabetes using glargine U-100 long-acting insulin therapy, ...

The European Commission posted a series of proposed legislative updates, including the AI Act, which might not come into ...

Radiopharm Theranostics Ltd. has been granted Bellberry Human Research Ethics Committee (HREC) approval in Australia to ...

Our goal is that by the end of this call, you’ll share our conviction in the totality of the data.” So said Agios Pharmaceuticals Inc. CEO Brian Goff as the company reported top-line data from its ...

The limited efficacy of cancer immunotherapy is usually attributed to suboptimal antitumor T-cell generation, as well as ...

Mabloc LLC has established a strategic partnership with Instituto Butantan to co-develop and manufacture MBL-YFV-01, a ...

In non-small-cell lung cancer (NSCLC) and various other cancers, mutations in nuclear factor erythroid 2-related factor 2 ...

Immunotherapy-focused biotech company LTZ Therapetics Inc. and GSK plc are partnering to develop up to four potential first-in-class myeloid cell engagers using LTZ’s immune-engager platform to target ...